Why Antidiabetic Vanadium Complexes are Not in the Pipeline of ""Big Pharma"" Drug Research? A Critical Review

dc.contributor.author	Laufer, Stefan
dc.date.accessioned	2019-02-12T09:00:25Z
dc.date.available	2019-02-12T09:00:25Z
dc.date.issued	2016
dc.identifier.issn	1875-533X
dc.identifier.uri	http://hdl.handle.net/10900/86326
dc.language.iso	en	de_DE
dc.publisher	Bentham Science Publ Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.2174/0929867323666160321121138	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	540	de_DE
dc.subject.ddc	570	de_DE
dc.subject.ddc	610	de_DE
dc.title	Why Antidiabetic Vanadium Complexes are Not in the Pipeline of ""Big Pharma"" Drug Research? A Critical Review	de_DE
dc.type	Article	de_DE
utue.quellen.id	20180405102126_04238
utue.publikation.seiten	2874-2891	de_DE
utue.personen.roh	Scior, Thomas
utue.personen.roh	Antonio Guevara-Garcia, Jose
utue.personen.roh	Do, Quoc-Tuan
utue.personen.roh	Bernard, Philippe
utue.personen.roh	Laufer, Stefan
dcterms.isPartOf.ZSTitelID	Current Medicinal Chemistry	de_DE
dcterms.isPartOf.ZS-Issue	25	de_DE
dcterms.isPartOf.ZS-Volume	23	de_DE
utue.fakultaet	07 Mathematisch-Naturwissenschaftliche Fakultät	de_DE